1
|
Han JH, Lee EJ, Park W, Ha KT, Chung HS. Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases. Front Pharmacol 2023; 14:1275000. [PMID: 37915411 PMCID: PMC10616500 DOI: 10.3389/fphar.2023.1275000] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Accepted: 09/27/2023] [Indexed: 11/03/2023] Open
Abstract
Lactate dehydrogenase (LDH) is a crucial enzyme involved in energy metabolism and present in various cells throughout the body. Its diverse physiological functions encompass glycolysis, and its abnormal activity is associated with numerous diseases. Targeting LDH has emerged as a vital approach in drug discovery, leading to the identification of LDH inhibitors among natural compounds, such as polyphenols, alkaloids, and terpenoids. These compounds demonstrate therapeutic potential against LDH-related diseases, including anti-cancer effects. However, challenges concerning limited bioavailability, poor solubility, and potential toxicity must be addressed. Combining natural compounds with LDH inhibitors has led to promising outcomes in preclinical studies. This review highlights the promise of natural compounds as LDH inhibitors for treating cancer, cardiovascular, and neurodegenerative diseases.
Collapse
Affiliation(s)
- Jung Ho Han
- Korean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu, Republic of Korea
| | - Eun-Ji Lee
- Korean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu, Republic of Korea
| | - Wonyoung Park
- Korean Convergence Medical Science Major, KIOM Campus, University of Science and Technology (UST), Daegu, Republic of Korea
| | - Ki-Tae Ha
- Korean Convergence Medical Science Major, KIOM Campus, University of Science and Technology (UST), Daegu, Republic of Korea
| | - Hwan-Suck Chung
- Korean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu, Republic of Korea
- Department of Korean Medical Science, School of Korean Medicine, Pusan National University, Yangsan, Republic of Korea
| |
Collapse
|
2
|
Wei J, Huang B, Nong Y, Zhang Q, Liu W, Xie Y, Peng T, Wang W, Liang X, Li Q, Liu F. Identification of a Novel Cuproptosis-Related Gene Signature in Eutopic Endometrium of Women with Endometriosis. Reprod Sci 2023; 30:1841-1853. [PMID: 36474131 PMCID: PMC10229735 DOI: 10.1007/s43032-022-01130-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Accepted: 11/14/2022] [Indexed: 12/12/2022]
Abstract
Endometriosis (EMs) is a life-long endocrine disorder and a common cause for female infertility and pelvic pain. The key characteristics of eutopic endometrium of EMs patients are high proliferative and migratory potentials. Cuproptosis is a recently identified copper- and-mitochondrial-dependent regulated cell death. Regretfully, its role in EMs remains unclear. In this study, Kyoto Encyclopedia of Genes and Genomes analyses of differentially expressed genes (DEGs) indicated strong activation of the PI3K-Akt-mTOR pathway and biological process analysis reported positive regulation of kinase activity. Next, we screened 11 cuproptosis-related DEGs and found all of them were downregulated in the EMs group, which indicated the suppression of cuproptosis in EMs. One key cuproptosis-related gene, PDHA1, was selected via support vector machine, random forest algorithm and lasso regularization to build a risk-scoring model, which was tested in both internal and external validations. In conclusion, the downregulation and kinase activity of PDHA1 may function with the PI3K-Akt-mTOR pathway in some way, which could suppress the cuproptosis level and account for the cancer-like pathology in EMs.
Collapse
Affiliation(s)
- Jiahui Wei
- Guangzhou Medical University, Guangzhou, 511495, China
- Department of Reproductive Health and Infertility, Guangdong Women and Children Hospital, Guangzhou, 511442, China
| | - Baoyi Huang
- Guangzhou Medical University, Guangzhou, 511495, China
| | - Yingqi Nong
- Department of Reproductive Health and Infertility, Guangdong Women and Children Hospital, Guangzhou, 511442, China
| | - Qianyu Zhang
- Department of Reproductive Health and Infertility, Guangdong Women and Children Hospital, Guangzhou, 511442, China
| | - Wenjuan Liu
- Department of Reproductive Health and Infertility, Guangdong Women and Children Hospital, Guangzhou, 511442, China
| | - Yanni Xie
- Department of Reproductive Health and Infertility, Guangdong Women and Children Hospital, Guangzhou, 511442, China
| | - Tong Peng
- Department of Reproductive Health and Infertility, Guangdong Women and Children Hospital, Guangzhou, 511442, China
| | - Wei Wang
- Guangzhou Medical University, Guangzhou, 511495, China
- Department of Reproductive Health and Infertility, Guangdong Women and Children Hospital, Guangzhou, 511442, China
| | - Xiangping Liang
- Guangzhou Medical University, Guangzhou, 511495, China
- Department of Reproductive Health and Infertility, Guangdong Women and Children Hospital, Guangzhou, 511442, China
| | - Qiuyun Li
- Guangzhou Medical University, Guangzhou, 511495, China
- Department of Reproductive Health and Infertility, Guangdong Women and Children Hospital, Guangzhou, 511442, China
| | - Fenghua Liu
- Department of Reproductive Health and Infertility, Guangdong Women and Children Hospital, Guangzhou, 511442, China.
| |
Collapse
|
3
|
Liu J, Yang D, Piao C, Wang X, Sun X, Li Y, Zhang S, Wu X. UPLC-Q-TOF/MS Based Plasma Metabolomics for Identification of Paeonol's Metabolic Target in Endometriosis. Molecules 2023; 28:molecules28020653. [PMID: 36677710 PMCID: PMC9864815 DOI: 10.3390/molecules28020653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2022] [Revised: 12/20/2022] [Accepted: 01/04/2023] [Indexed: 01/11/2023] Open
Abstract
Endometriosis is a common gynecological illness in women of reproductive age that significantly decreases life quality and fertility. Paeonol has been shown to play an important part in endometriosis treatments. Understanding the mechanism is critical for treating endometriosis. In this study, autologous transplantation combined with a 28 day ice water bath was used to create a rat model of endometriosis with cold clotting and blood stagnation. The levels of estradiol and progesterone in plasma were detected by ELISA, and the pathological changes of ectopic endometrial tissue were examined by H&E staining, which proved the efficacy of paeonol. For metabolomic analysis of plasma samples, UPLC-Q/TOF-MS was combined with multivariate statistical analysis to identify the influence of paeonol on small molecule metabolites relevant to endometriosis. Finally, the key targets were screened using a combination of network pharmacology and molecular docking approaches. The results showed that the pathological indexes of rats were improved and returned to normal levels after treatment with paeonol, which was the basis for confirming the efficacy of paeonol. Metabolomics results identified 13 potential biomarkers, and paeonol callbacks 7 of them, involving six metabolic pathways. Finally, four key genes were found for paeonol therapy of endometriosis, and the results of molecular docking revealed a significant interaction between paeonol and the four key genes. This study was successful in establishing a rat model of endometriosis with cold coagulation and blood stagnation. GCH1, RPL8, PKLR, and MAOA were the key targets of paeonol in the treatment of endometriosis. It is also demonstrated that metabolomic techniques give the potential and environment for comprehensively understanding drug onset processes.
Collapse
Affiliation(s)
- Jing Liu
- College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China
| | - Dongxia Yang
- Department of Gynecology Medicine, Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin 150001, China
| | - Chengyu Piao
- Good Laboratory Practice of Drug, Heilongjiang University of Chinese Medicine, Harbin 150040, China
| | - Xu Wang
- Good Laboratory Practice of Drug, Heilongjiang University of Chinese Medicine, Harbin 150040, China
| | - Xiaolan Sun
- College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China
| | - Yongyan Li
- College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China
| | - Shuxiang Zhang
- College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China
| | - Xiuhong Wu
- College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China
- Correspondence: ; Tel.: +86-451-82193278
| |
Collapse
|